ArticleMedicine2026
Efficacy and safety of modified transurethral thulium laser enucleation-resection with apical vaporization cutting versus anatomic thulium laser enucleation for large-volume (> 80 ml) benign prostatic hyperplasia: A retrospective comparative study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare the perioperative outcomes, efficacy, and safety of modified transurethral thulium laser enucleation-resection (ThuLERP) versus standard anatomic thulium laser enucleation (ThuLEP) for large-volume benign prostatic hyperplasia (BPH) (> 80 ml), with a primary focus on early urinary continence recovery. We retrospectively analyzed 215 patients with large-volume BPH treated between January 2021 and December 2024. Patients were segregated into the ThuLERP group (n = 110), receiving anatomical enucleation of the middle and lateral lobes combined with vaporization cutting at the prostatic apex and anterior commissure, or the ThuLEP group (n = 105), undergoing traditional 3-lobe anatomical enucleation. Baseline characteristics, including prostate volume (102.5 ± 21.3 ml vs 104.1 ± 22.5 ml), were comparable between groups. Primary outcomes assessed continence at 1 week, 1 month, and 3 months; secondary outcomes evaluated perioperative metrics and functional recovery at 6 months. All procedures were successful. The ThuLERP group demonstrated significantly shorter total operation time (65.2 ± 18.5 minutes vs 79.4 ± 20.1 minute, P < .01) and enucleation time (48.1 ± 15.3 minutes vs 62.5 ± 17.8 minutes, P < .01) compared to ThuLEP. Safety outcomes favored ThuLERP, showing a lower incidence of postoperative hematuria requiring intervention (6.4% vs 12.4%, P < .05) and no reoperations for bleeding in the ThuLERP group compared to 1.9% in the ThuLEP group, although this difference was not statistically significant (P > .05). Notably, ThuLERP resulted in superior early continence: incontinence rates were significantly lower at 1 week (8.2% vs 21.9%, P < .01) and 1 month (2.7% vs 9.5%, P < .05). By 3 months, continence rates were comparable (> 98%). Both groups achieved similar significant improvements in International Prostate Symptom Score, quality of life, maximum urinary flow rate, and post-void residual at 6 months. Modified ThuLERP is as effective as standard ThuLEP regarding long-term functional outcomes for large-volume BPH. However, it offers distinct advantages by reducing operative time, improving hemostasis, and significantly accelerating the recovery of early urinary continence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.